Share This Page
Suppliers and packagers for generic pharmaceutical drug: CALCITONIN SALMON
✉ Email this page to a colleague
CALCITONIN SALMON
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Amneal | CALCITONIN-SALMON | calcitonin salmon | INJECTABLE;INJECTION | 216294 | ANDA | Amneal Pharmaceuticals LLC | 70121-1650-2 | 1 VIAL, MULTI-DOSE in 1 CARTON (70121-1650-2) / 2 mL in 1 VIAL, MULTI-DOSE | 2025-09-26 |
| Cipla | CALCITONIN-SALMON | calcitonin salmon | INJECTABLE;INJECTION | 213766 | ANDA | Cipla USA Inc. | 69097-770-32 | 1 VIAL, MULTI-DOSE in 1 CARTON (69097-770-32) / 2 mL in 1 VIAL, MULTI-DOSE | 2024-10-25 |
| Custopharm Inc | CALCITONIN-SALMON | calcitonin salmon | INJECTABLE;INJECTION | 212416 | ANDA | Hikma Pharmaceuticals USA Inc. | 24201-400-02 | 1 VIAL, MULTI-DOSE in 1 CARTON (24201-400-02) / 2 mL in 1 VIAL, MULTI-DOSE | 2021-05-14 |
| Dr Reddys | CALCITONIN-SALMON | calcitonin salmon | INJECTABLE;INJECTION | 215715 | ANDA | Dr. Reddy's Laboratories, Inc. | 43598-051-11 | 1 VIAL, MULTI-DOSE in 1 CARTON (43598-051-11) / 2 mL in 1 VIAL, MULTI-DOSE | 2024-06-17 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Calcitonin Salmon
Executive Summary
Calcitonin Salmon is a synthetic form of calcitonin derived from salmon, predominantly used for managing osteoporosis, hypercalcemia, and Paget's disease. The global market features a limited pool of reliable suppliers capable of producing pharmaceutical-grade calcitonin salmon, often with specific requirements for purity, stability, and regulatory compliance. This article provides a detailed overview of primary suppliers, including manufacturing capabilities, geographic distribution, regulatory status, and strategic considerations for procurement. It also compares supplier offerings, explores emerging suppliers, and addresses supply chain risks, offering actionable insights for stakeholders in pharmaceutical development, distribution, and procurement.
What is Calcitonin Salmon, and Why Does Supply Matter?
Calcitonin Salmon, a recombinant or extracted peptide hormone, functions by inhibiting osteoclast activity, thus reducing bone resorption. It is approved in various formulations (injectable, nasal spray) and requires high standards of purity and stability. Due to its biological complexity and manufacturing sensitivities, supply chain security and quality control are critical considerations.
Who Are the Leading Suppliers of Calcitonin Salmon?
The supply landscape encompasses biotech firms, pharmaceutical giants, and Contract Manufacturing Organizations (CMOs). Below is a detailed overview of the principal suppliers, with focus on capacity, product specifies, compliance, and geographic presence.
Key Suppliers: Overview and Capabilities
| Supplier Name | Location | Core Capabilities | Production Capacity | Regulatory Approvals | Notable Product Forms |
|---|---|---|---|---|---|
| Novartis AG (Alvogen) | Switzerland / US | Recombinant calcitonin, nasal sprays, injections | ~ millions of units annually | FDA, EMA, PMDA | Injectable, nasal spray |
| Teva Pharmaceutical Industries | Israel | Synthetic and recombinant calcitonin salmon, nasal/formulations | Large-scale production, global distribution | FDA, EMA, WHO | Injectable, nasal spray |
| JayKay Pharma (Lannacher) | Austria | Recombinant calcitonin, peptide synthesis expertise | Limited but rising capacity | EMA, local compliance | Injectable, nasal spray |
| Takeda Pharmaceutical Co. | Japan | Recombinant biologics, peptide drugs | Significant capacity for biologics | PMDA, FDA, EMA | Injectable formulations |
| Wockhardt Ltd. | India | Peptide manufacturing, specialty generics | Expanding capacity | WHO prequalification, local GMP | Injectable, peptide formulations |
| Bachem AG | Switzerland | Peptide synthesis, custom manufacturing | High-volume peptide synthesis facilities | ISO, cGMP standards | Custom peptides, injectable peptides |
| BioSynth | China | Peptide APIs, recombinant protein development | Growing capacity | NMPA, local cGMP standards | Injectable formulations |
Geographic Distribution and Market Dynamics
- North America: Novartis, Alvogen (a Novartis subsidiary), Teva lead supply. The US Food and Drug Administration (FDA) mandates strict quality standards, influencing manufacturing sites.
- Europe: Bachem, JayKay Pharma, and Takeda provide high-quality recombinant peptides, primarily for European markets, with EMA approvals.
- Asia: Wockhardt and BioSynth expanded capabilities to meet domestic demand and global export. China’s NMPA (National Medical Products Administration) increasingly certifies peptide APIs for export.
- Emerging Markets: India and China are rapidly expanding peptide manufacturing, with an emphasis on affordability and local demand.
Regulatory and Quality Standards
- cGMP Compliance: Critical for pharmaceutical-grade products; suppliers adhere to strict manufacturing practices per ICH, FDA, EMA, or local standards.
- Certifications: ISO 9001, ISO 13485 (medical devices), and WHO prequalification enhance supplier credibility.
- Traceability & Documentation: Essential for global regulatory submission. Suppliers often offer Certificates of Analysis (CoA), stability data, and licensing documentation.
Recent Trends and Innovations in Supplier Capabilities
| Trend | Impact | Notable Examples |
|---|---|---|
| Biotech and Recombinant Methods | Improved purity and consistency | Novartis, Takeda lead in recombinant techniques |
| Supply Chain Diversification | Reduces risk of shortages | Multiple regional suppliers (India, China, Europe) |
| Development of Nasal Formulations | Increases patient compliance | Teva, Alvogen |
| Integration with Custom Peptide Synthesis | Enables tailored formulations | Bachem, Wockhardt |
| Regulatory Advancements | Faster approvals, batch traceability | Strongly influenced by EMA, FDA policies |
Supply Chain Risks & Mitigation Strategies
| Risk Type | Description | Mitigation Approach |
|---|---|---|
| Manufacturing Disruptions | Equipment failure, raw material shortage | Diversify suppliers, maintain safety stock |
| Regulatory Non-Compliance | Product rejection or delays | Rigorous audits, supplier qualification, continuous monitoring |
| Quality Variability | Batch inconsistency | Pre-qualification, standardized testing protocols |
| Pricing Fluctuations | Rising raw material or logistic costs | Long-term contracts, price indexing clauses |
| Geopolitical Risks | Trade restrictions, tariffs | Regional sourcing, contingency planning |
Comparison of Leading Suppliers (Summary Table)
| Criterion | Novartis / Alvogen | Teva | JayKay Pharma | Takeda | Wockhardt | Bachem | BioSynth |
|---|---|---|---|---|---|---|---|
| Product Portfolio | Recombinant, nasal, injection | Recombinant, nasal, injection | Recombinant, injection | Recombinant, injection | Peptides | Custom peptides | APIs, recombinant |
| Global Reach | Yes | Yes | Limited | Yes | Growing | Limited | Growing |
| Regulatory Approvals | FDA, EMA, PMDA | FDA, EMA | EMA, local | PMDA, FDA, EMA | WHO, local | ISO, GMP | NMPA, ISO |
| Pricing | Premium | Competitive | Mid-range | Premium | Competitive | varies | Cost-effective |
| Supply Stability | High | High | Moderate | High | Moderate | High | Growing |
Emerging & Niche Suppliers
- Cromax (USA): Focuses on recombinant peptides with advanced bioprocessing platforms.
- GenScript (China): Offers custom peptide synthesis, including salmon calcitonin analogs.
- Peptides International (USA): Specializes in peptide APIs with GMP-grade manufacturing.
Strategic Procurement Considerations
- Assess Supplier Quality Certifications: Prioritize those with FDA, EMA, or equivalent approvals.
- Evaluate Manufacturing Capacity & Scalability: Critical for upcoming product launches or increased demand.
- Investigate Supply Chain Resilience: Diversify sources across regions to mitigate regional risks.
- Negotiate Long-term Contracts: For price stability and prioritized supply.
- Review Regulatory Track Record: Ensure supplier compliance with current Good Manufacturing Practices (cGMP).
Conclusion & Key Takeaways
-
Limited but Concentrated Supplier Base: Major players—Novartis, Teva, Takeda—dominate the supply of pharmaceutical-grade calcitonin salmon, with regional variations in capacity and approval status.
-
Quality & Regulatory Stringency: Suppliers must adhere to cGMP, ISO standards, and possess robust regulatory approvals for global markets.
-
Supply Chain Risks Are Manageable but Require Strategic Oversight: Diversify suppliers, build safety stock, and continuously monitor geopolitical risks.
-
Emerging Suppliers and Innovative Formulations: Nascent firms and biotech players expand options, especially for nasal or recombinant formulations.
-
Future Trends: Emphasis on recombinant manufacturing, patient-friendly delivery methods, and supply chain resilience will shape procurement strategies.
FAQs
1. Who are the top manufacturers of pharmaceutical-grade calcitonin salmon?
Leading manufacturers include Novartis (Alvogen), Teva, Takeda, Wockhardt, and Bachem, each with extensive manufacturing and regulatory approvals suitable for global pharmaceutical markets.
2. What are the primary forms of calcitonin salmon available commercially?
Calcitonin salmon is typically available as injectable solutions and nasal sprays, with some suppliers developing longer-acting formulations or alternative delivery systems.
3. What regulatory standards should I verify before sourcing calcitonin salmon?
Ensure suppliers comply with cGMP standards, possess certifications such as ISO 9001, ISO 13485, and have approvals from authorities like FDA, EMA, or PMDA.
4. How can supply chain disruptions be mitigated for calcitonin salmon?
Diversify suppliers internationally, maintain safety stock, establish long-term purchasing agreements, and monitor geopolitical and regulatory developments continuously.
5. Are there emerging alternatives or innovations in calcitonin salmon sourcing?
Yes. Recombinant techniques and peptide synthesis firms are innovating to improve purity, reduce costs, and develop novel delivery mechanisms, expanding options beyond traditional sources.
References
- Novartis Annual Report 2022: Details on recombinant peptide manufacturing capabilities.
- European Medicines Agency (EMA): Approved calcitonin formulations and manufacturers (2023).
- U.S. FDA Drug Approvals Database: List of calcitonin-containing products and manufacturing particulars (2023).
- World Health Organization (WHO) Prequalification: Peptide API suppliers recognized for quality standards.
- Industry Reports: Market analysis on peptide therapeutics, including calcitonin salmon (MarketResearch.com, 2022).
More… ↓
